Literature DB >> 32212134

Hepatocellular Carcinoma Recurrence After Liver Transplantation.

Alejandro Gabutti, Sherrie Bhoori, Tommaso Cascella, Marco Bongini.   

Abstract

Key Points • Recurrent HCC after OLT management is challenging and notoriously difficult. • High oncologic-risk patient identification and close follow-up are essential. • Recurrences diagnosed within the first 2 years after OLT can be classified as early-onset and are associated with poor prognosis. • Surgical resection should be the first curative attempt when it is technically feasible. • TACE in patients who have undergone OLT appears to be effective and safe. • Sorafenib can be used as systemic therapy in cases with multi-organ recurrence; newer therapies are emerging. • The benefit of immunosuppression with an mTOR inhibitor has not been established. • In the posttransplant setting, a combination treatment approach is warranted.

Entities:  

Mesh:

Year:  2020        PMID: 32212134

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  1 in total

1.  Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver Transplantation.

Authors:  Okjoo Lee; Jinsoo Rhu; Gyu-Seong Choi; Jong Man Kim; Kyunga Kim; Jae-Won Joh
Journal:  Ann Transplant       Date:  2022-04-05       Impact factor: 1.530

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.